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A
cancer immune signature implic-
ating good prognosis and respon-
siveness to immunotherapy was described
that is observed also in other aspects
of immune-mediated, tissue-specific
destruction (TSD). Its determinism
remains, however, elusive. Based on
limited but unique clinical observations,
we propose a multifactorial genetic model
of human cancer immune responsiveness.
…answers preexist, and it is the question
that needs to be discovered.
—Jonas Salk
1
Introduction
Among the infinite permutations that
deductive thinking applied to the current
understanding of biology may conceive,
only a few materialize because Nature
adopts a handful to achieve its goals.
2 For
instance, a deductive approach could
hypothesize an infinite number of limbs
protruding from a mammalian body,
but in reality only four are observed as
evolution decided long ago that this is
quite suitable for most creatures’ survival.
An immunologic example is the realization
by Hancock et al.
3 that, “although almost
every known chemokine and chemokine
receptor is expressed at some stage during
development of allograft rejection, mecha-
nistic studies indicate that the actual key
effector mechanisms are rather few. Thus,
in vivo studies have alleviated concerns
regarding possible biological redundancy
and the pleiotropic effects of these mole-
cules, and have resulted in a focus on
CXCR3, CCR5 and their respective
ligands as key mediators of host allore-
sponses, especially in acute rejection.”
Interestingly, a bottom up, inductive
approach applied to the study of human
tissues undergoing rejection reached the
same conclusion without need to test an
infinite number of conceivable combina-
tions.
4-6 For this reason, we advocated that
an inductive approach based on human
observation may alleviate the daunting task
of predicting in the laboratory what can
be directly observed in nature.
2 Follow-
ing this observational approach, various
groups concluded that human cancer
biology can be simplified according to
recurring immunologic themes.
7 An
observation pertinent to this manuscript
suggests that some cancers display an
effector immune phenotype associated
with good prognosis.
8 Concurrent with
this observation, is the realization that a
similar footprint is observable in cancers
likely to regress in response to active-
specific vaccination,
9 treatment with sys-
temic interleukin (IL)-2
10 or other types
of immune therapy.
7 Paradoxically, since
these signatures are observed in growing
cancers, they are not sufficient to clear
entirely the organism of neoplastic cells
but they sustain, as in chronic infections, a
self-perpetuating inflammatory process
that may slow cancer growth naturally
and predispose to cancer rejection during
immunotherapy.
6 More broadly, the same
signatures are observed in tissues under-
going other types of immune-mediated
tissue-specific destruction (TSD) such as
flares of autoimmunity, killing of patho-
gen-infected cells during acute infection,
allograft rejection and graft-vs. host dis-
ease.
5 The convergence of these pheno-
mena into a common final pathway
suggests that TSD is a conserved mech-
anism mediated by the activation of a
specific set of genes that we named the
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immunologic constant of rejection (ICR).
4
We suggested that the ICR includes at
least four components: the activation of
the signal transducer and activator of
transcription (STAT)-1/interferon regula-
tory factor (IRF)-1 pathway resulting in
the activation of interferon (IFN)-c
stimulated genes (ISGs), the expression
of immune effector (IEFs) mechanisms
and the CXCR3 and the CCR5 ligand
chemokines.
5 While the common pathway
to rejection (how does rejection occur)
is becoming progressively accepted, the
factors determining its occurrence in
individual cases (why does rejection occur)
remain elusive. It is likely that while TSD
results from a common pathway depend-
ing upon the activation of ICR genes,
the upstream factors leading to TSD in
individual cases are heterogeneous and
disease-specific. Consequently, it is likely
that the genetic and environmental factors
predisposing to distinct immune patholo-
gies are different and the genesis of TSD is
multifactorial; conditions leading to TSD
may be overlapping, mutually exclusive or
synergist making the algorithm leading to
rejection difficult to identify and unyield-
ing to univariate comparisons as combina-
tions rather that individual factors may
be at the basis of the phenomenon. This
view point will summarize our efforts
to apply a discovery-driven, systematic
approach to the identification of deter-
minants of cancer immune responsiveness.
The Natural History of Cancers
is Linked to its Immune Phenotype
The connotation of lymphocytic infiltrates
as a favorable prognostic biomarker in
cancer was originally reported by Cochran
et al.
11 in 1969; however, much progress
has been made in the last decade in
particular by Jérôme Galon who charac-
terized extensively the type and functional
status of immune infiltrates associated
with good prognosis in colon cancer.
7,8
In particular, the expression of genes
associated with a Th1 effector T-cell
response was observed to bear superior
prognostic accuracy compared with TNM
staging; this lead to an effort to evaluate
immune scoring as a new approach to
complement the current classification of
cancer.
12 Others subsequently reported
similar findings in melanoma, ovarian,
breast and squamous cell cancer.
7 Thus,
it appears that the Th1 environment
originally described for colon cancer is a
widespread phenomenon related to the
oncogenic process rather than the onto-
geny of individual cancers. Although, a
classification of cancer based on its
immune phenotype has not been as yet
broadly embraced for routine diagnostic
and staging purposes, the confirmation
by various groups including ours
13 of
these findings sheds a new light on the
understanding of the immune biology of
cancer. Thus, future work will be aimed
at understanding the mechanism leading
to this cancer phenotype whether this is
dependent upon the genetic background
of the host, the genetic makeup of indivi-
dual cancers, environmental influences or
a combination of them.
The Effector Immune Phenotype
of Cancer also Predicts Immune
Responsiveness
Concurrent to the previous observations,
others observed that the expression of
ISGs, IEFs and CXCR3 and CCR5
ligand chemokines was predictive of
tumor responsiveness to immunotherapy
such as vaccination with antigenic pep-
tides, dendritic cell-based vaccines and
systemic cytokine therapy.
7 About a
decade ago, we observed that melanoma
metastases likely to regresss following
immune therapy with active specific
vaccination and systemic IL-2 therapy,
displayed before treatment an activate
immune microenvironment.
14 We were
recently able to confirm this finding in a
small prospective study in which patients
with metastatic melanoma were treated
with systemic IL-2 and their metastases
were serially biopsied with fine needle
aspiration biopsies (FNA) before and
during treatment.
10 This approach directly
links the biology of individual lesions to
their responsiveness to treatment.
14-16 In
two patients, pre-treatment biopsies
clearly identified lesions destined to
respond, which expressed the ICR signa-
ture.
10 A more extensive unpublished
study in which patients with melanoma
or lung cancer were treated with a MAGE-
A3 peptide plus adjuvant confirmed these
signatures as harbinger of good outcome.
9
We recently summarized these and similar
observations in a more comprehensive
review beyond the purposes of this article.
7
The Immune Responsive
Phenotype is Enhanced
in Responsive Lesions
During Treatment
Immunologic patterns that define the
good prognostic phenotype are qualita-
tively similar to those observed during
TSD.
5,6 By obtaining serial FNA biopsies
of melanoma metastases during and/or
following therapy, we observed a decade
ago
14 that lesions undergoing rejection
displayed enhanced expression of IRF-1,
which later became recognized as the
master regulatory transcription factor
modulating the switch from chronic to
acute inflammation during TSD.
17 The
observation was expanded subsequently
to a complete set of genes associated to
the ICR; in a double blind randomized
placebo control study, we serially biopsied
basal cell carcinomas undergoing TSD
following treatment with the Toll-like
receptor agonist Imiquimod and identified
a rejection-specific signature.
18,19 The set
of genes associated with the rejection of
basal cell carcinoma in patients receiving
Imiquimod, was then observed in several
other types of TSD following different
treatments, in different diseases and even
in different mammalian species
5,7,20 con-
firming the breath of the phenomenon.
Most recently, by prospectively following
serially biopsied melanoma metastases in
patients treated with high dose systemic
IL-2, we could document the switch from
a moderate activation of ICR genes in
pre-treatment lesions to a fully blown
activation during treatment only in
lesions that eventually underwent com-
plete regression.
10 Since the signatures
observed pre-treatment in responsive
lesions were qualitatively similar to those
observed during treatment, we postulate
that the biology underlining immune
responsiveness is a necessary pre-existent
requirement that is however not sufficient
for tumor rejection. Thus, immune-
mediated rejection of tumors reflects a
continuum that spans from an indolent
immune recognition that may slow but
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not stop in natural conditions tumor
growth to a potent activation of acute
inflammation that embraces the complete
set of effector components necessary for
tissue rejection during immune stimu-
lation. Similarly, comparison of metastases
from two patients who experienced a
mixed response following immunotherapy
identified the activation of ICR genes
in the responding but not in the non
responding lesions.
16
The Activation of ICR Genes
During Cancer Rejection is Shared
by Other Immune Pathologies
Suggesting that Cancer Rejection
is a Form of Autoimmunity
The signatures identified in immune
responsive lesions before treatment and
that are amplified during and/or following
treatment are similar to those observed
during other forms of TSD such as
allograft rejection, graft vs. host disease,
clearance of pathogen and flares of auto-
immunity.
4,5,21 Among them, autoimmu-
nity is the one that most closely resembles
tumor rejection as it is the only one
directed toward self. Thus, we suggest
that tumor rejection whether occurring
spontaneously or induced by immune
manipulation is a form of tissue-specific
autoimmunity directed against the neo-
plastic organ. Indeed, immune responsive-
ness of melanoma to various treatments
including systemic IL-2 administration or
IFNa, has been associated with various
forms of autoimmunity including viti-
ligo,
22 thyroiditis,
23 autoimmune rethyno-
pathy
24 and development of antibodies
against self.
25 While the association
between vitiligo and rejection of mela-
noma may represent the immune response
against antigens shared by cells of the
melanocytic lineage, the reason for the
association with other autoimmune dis-
eases remains to be clarified as it could
represent a response to still unknown
shared antigens or reflect a status of hyper
immune activation. Among the various
manifestations of autoimmunity, a quite
aggressive is systemic lupus erythematosus
(SLE). A clear link between SLE and
responsiveness to immunotherapy has
never been described. This could be partly
explained by the preferential exclusion of
patients with severe autoimmunity from
immunotherapy trials. It was, however,
observed that symptoms related to SLE
could be exacerbated by immunotherapy
in cases when patients were enrolled.
26
Moreover, patterns associated with tumor
rejection are similar to SLE as they share
a relatedness in ISG activation;
27,28 this
observation lead us to study whether
genetic traits associated to the develop-
ment of SLE could also apply to cancer
immune responsiveness.
The Immune Phenotype
Associated with Immune
Responsiveness is Partly
Dependent upon the Genetics
of the Host
As discussed in the previous paragraph, if
autoimmunity is associated with cancer
immune responsiveness, polymorphisms
of genes related to the former might be
associated with the latter. We studied
recently patients enjoying better overall
survival following treatment with IFNa.
We observed that patients carrying either
DRB1*15 or HLA-Cw7 suffered worse
overall survival while patients with either
HLA-Cw6 or HLA-B44 enjoyed a better
one. In addition to HLA, CTLA4 poly-
morphism was identified as a marker
associated with shorter overall survival.
Importantly, multivariate analysis revealed
that a five-marker genotyping signature
bore even better prognostic significance.
A multivariate Cox regression model
demonstrated that the presence of HLA-
B38, HLA-C15, HLA-C3, DRB1*15 and
the CTLA4 polymorphisms CT60*G/G
(0.081) were significantly associated with
overall survival suggesting that genetic
factors predisposing to immune respon-
siveness may be multiple and analysis of
them in combination may be more
informative than studying each separ-
ately.
29 Others have looked at the D32
variant of CCR that induces the expres-
sion of a non functional protein; patients
with melanoma carrying this polymorph-
ism were observed to score worse after
immunotherapy.
30 Perhaps, the most
striking link between the genetic charac-
teristic of the host and immune respon-
siveness came from a recent study that
we performed in patients with melanoma
treated with the adoptive transfer of ex
vivo activated tumor infiltrating lympho-
cytes. Analysis of IRF-5 polymorphisms
previously described to be associated with
protection from developing SLE demon-
strated that the same where highly pre-
dictive of non-responsiveness to melanoma
(Uccellini et al., manuscript in prepara-
tion). Importantly, we observed that
metastases from patients carrying this
variant of IRF-5 displayed a distinct
transcriptional pattern. Moreover, mela-
noma cell lines derived from the same
metastases displayed in vitro distinct
transcriptional patterns between the two
genotypes that could be used to impute
immune responsiveness of the parental
metastases. This observation suggests that
germline variants can affect directly the
intrinsic biology of cancer cells besides
affecting the behavior of host’s cells.
The Immune Phenotype
Associated with Immune
Responsiveness is Partly
Dependent Upon the Genetics
of the Cancer
The most striking evidence that immune
responsiveness is, at least in part, related
to acquired alterations of cancer cell
genetics is the phenomenon of the mixed
responses. A proportion of cancer patients
experience a mix response to therapy
characterized by the simultaneous regres-
sion of some metastases, while other
progress. These relatively rare cases are
precious since they single out the tumor’s
aspects of immune responsiveness exclud-
ing from the equation the genetic back-
ground of the patient or external factors
affecting the effectiveness of treatment.
We recently performed a comparative gene
expression analysis of 15 metastases (10
regressing and 5 progressing) obtained
from two melanoma patients experiencing
a mixed response following immunother-
apy.
16 Transcriptional analysis indicated
that regression of melanoma metastases
is associated with acute inflammation
mediated by the upregulation of genes
involved in antigen presentation, which
in turn are activated downstream of the
STAT-1/IRF-1 pathway. The molecular
signature obtained in regressing metastases
was similar to that observed in other types
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of TSD supporting the ICR hypothesis.
This limited but unique study provides
a striking demonstration that within the
same genetic background and identical
therapeutic conditions, tumors can behave
differently and, therefore, that tumor
rejection is at least in part dependent
upon tumor biology.
A Proposed Algorithm Governing
Immune Responsiveness
of Human Cancers that Includes
the Genetic Background
of the Host and Somatic
Alterations of Cancer
The last two paragraphs are in apparent
contrast; on one side it appears that the
genetic background of the host’s bears
significantly on immune responsiveness,
on the other it appears that tumor can
behave differently within the same genetic
background. This apparent paradox can
only be explained by a multi-factorial
model of cancer immune responsiveness.
It should be emphasized that host and
cancer genetics are largely overlapping
since cancer cells carry the majority
of the host’s genetics (Fig.1). Thus,
inherited genetic factors may affect the
biology of cancer cells besides that of
normal cells. Thus, it could be postulated
that some patients carry a genetic back-
ground that make them resistant to
immunotherapy by effecting either the
biology of the immune response, the
biology of the cancer cells or both. On
the other hand, “an immune-responsive
genotype” may still be limited by the
genetics of the tumors: in other words,
although the patient may be predisposed
to cancer rejection the tumor lacks addi-
tional properties necessary for its recogni-
tion by the immune response (Fig.2). In
this model, a favorable genetic background
of the host is necessary but not sufficient
for tumor rejection as the possession of a
shotgun is necessary to shoot a duck but
at the same time a skill in shooting is
required. A good example is provided
by the analysis of patients with IRF-5
polymorphism; the “immune resistant
phenotype” appears to almost exclusively
preclude cancer rejection during adoptive
therapy with tumor infiltrating lympho-
cytes; however, “the immune responsive
phenotype” can be segregated into two
categories; one enriched in patients res-
ponding to therapy and the other of non-
responding. Although, other host’s genetic
factors could be responsible for this sub-
classification, it is also possible that, given
a favorable genetic background, the
genetics of the tumor may become the
determining factor.
We recognize that this classification of
factors that may influence immune res-
ponsiveness may be too rigid. In reality,
immune responsiveness may depend upon
a continuum determined by the inter-
action of a multitude of factors that for
simplicity can be separated into broad
categories depending upon the host’s
genetic background, somatic mutations,
and external factors such as intensity and
effectiveness of treatment, general con-
dition of the patient and a multitude of
other hidden co-factors (Fig.3).
Figure1. Interplay among categorical modifiers of responsiveness. (A) Classical view of the relationship between host genetic background, tumor
genetics and environmental factors. (B) A more likely scenario integrating the large overlap between the genetics of the host and the tumor
and the over-reaching effect of environmental factors on both of them.
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Figure2. Check point regulating the winding road to cancer immune responsiveness. The host’s genetic may be the first limiting factor and a genetic
predisposition to immune response may be necessary but not sufficient to allow cancer response to immunotherapy. Subsequently, genetic alteration
of cancer cells may allow escape from immune recognition in spite of a favorable genetic background. Finally, quality and intensity of treatment and
a myriad of hidden external factors may determine the final outcome.
Figure3. A quantitative continuum determining the responsiveness of tumors according to genetic background of the host, genetics of cancer cells,
effectiveness of treatment and other “hidden” external factors that may affect the final outcome.
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We acknowledge that these conclu-
sions are speculative but we hope that
this commentary may stimulate an inte-
grated approach to the study of cancer
patients receiving immunotherapy that
includes the analysis of germline variants,
tumor genetics and other post-genomic
modifications.
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